Next Up

Digital Biomarkers & Pathology Symposium

07 December 2021 |

EDT (UTC-4)

07 December 2021

EDT (UTC-4)

Learn how the latest digital technologies can transform the future of healthcare and the clinical trials process

07 Feb 2022
Mon, 07 February 2022

Biomarkers US: In-Person

Gain a US perspective on the latest technologies and novel biomarkers driving forward translational research and precision medicine

03 May 2022
Tue, 03 May 2022

Biomarkers UK: In-Person

Europe’s flagship event for Biomarker Research Returns: the must-attend forum to engage with the latest trends transforming biomarker and translational research

13 Sep 2022
Tue, 13 September 2022

Biomarker Analysis: Online

Highlights

Biopsy For Easy and Difficult Cancer
Commentary
Liquid biopsy has the potential to become a transformative cancer management and therapeutic strategy within the next 5 to 10 years. However, its capability across all cancer stages largely depends upon assay sensitivity. In this commentary piece, the University of Edinburgh’s Tim Aitman takes us through a novel approach set to pioneer the landscape of liquid biopsy.
By Tia Byer |
01 December 2021
Biomarker Technologies
Insight Article
By Tia Byer |
08 Nov 2021
Biomarker Technologies
Commentary
By Tia Byer |
04 Nov 2021
Biomarker Technologies

Insights

Commentary
Liquid biopsy has the potential to become a transformative cancer management and therapeutic strategy within the next 5 to 10 years. However, its capability across all cancer stages largely depends upon assay sensitivity. In this commentary piece, the University of Edinburgh’s Tim Aitman takes us through a novel approach set to pioneer the landscape of liquid biopsy.
01 December 2021
Insight Article
With an increasing need for large data analysis and validation, this Insight article takes an in-depth look at some of the recent advances in automation technologies affecting the flow cytometry field.
08 November 2021
Commentary
How can the biomarkers industry best implement multi-parameter flow cytometry in clinical drug development? Vilma Decman of GlaxoSmithKline takes us through the advantages of using spectral flow cytometry, the importance of viability dyes, and high-parameter panel design.
04 November 2021
Insight Article
Qing Kang-Fortner, Ph.D., Senior Scientist, Translational Medicine, Syros Pharmaceuticals, Inc
08 October 2019

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Biomarkers

Submit your details to receive the monthly newsletter & to be kept up to date about relevant events, monthly discussion groups and portal membership offers. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.